

Strong Recruitment Progress in Alzheimer's Trial

- **Enrolment into XanADu remains robust and on track**
- **Total of 72 patients enrolled, representing 41% of the full enrolment**
- **Study on track to enrol the final patient in Q4 this year**
- **Xanamem has the potential to provide a global solution to a significant unmet medical need**
- **Actinogen's novel approach to treating Alzheimer's disease represents a compelling investment opportunity**

Sydney, 12 February 2018: Actinogen Medical (ASX: ACW) is pleased to provide an update on the recruitment progress for its landmark Alzheimer's disease trial, XanADu. XanADu is assessing the efficacy and safety of Xanamem in the treatment of Alzheimer's disease.

As of 12th February, 72 patients have been enrolled into the trial, representing 41% of the total enrolment of 174 patients. Additionally, more than 30 patients have completed the study, including the 12-week treatment period and the 4-week follow-up.

The study continues on schedule, with the final patient expected to be enrolled by Q4 this year.

Alzheimer's disease is already the leading cause of death in Australian women, and second only to cardiovascular disease in Australian men (ABS 2017). The future cost of managing Alzheimer's disease is likely to overwhelm available health budgets, and with only four marginally effective drugs available to treat the condition, there is an urgent need to develop new therapies to manage the disease.

Should Xanamem be shown to be effective in the treatment of Alzheimer's disease, it would be the most meaningful advance in Alzheimer's treatment in decades, representing a rare and compelling investment opportunity.

"Having spent the majority of my career working within the biotech venture capital investment industry, I am well aware of the enormous challenges and commonplace delays involved in clinical trial enrolment. It is encouraging therefore to see the excellent progress being made by the Actinogen Medical team in enrolling patients into the XanADu trial. It's an impressive achievement to be right on schedule with patient enrolment." said Dr Geoff Brooke, Chairman Actinogen Medical

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.